OP Team steps up
PharmNovo AB is pleased to announce that the company has strengthened the team when entering the clinical phase with PN6047. Tommy Nilsson takes on the role of CFO, and Jarkko Kalliomäki will support clinical management and work with the design and development of clinical studies.
In August, PharmNovo started clinical studies of its drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain, after raising SEK 73 million in an issue led by Sciety earlier this summer.
Tommy Nilsson has a background as CFO at subsidiaries of Electrolux and Ericsson. He has worked as interim CFO for businesses in several industries for the past years. At PharmNovo, he will lead financial management and reporting, build up the company's routines and processes, and prepare the company for future follow-on financing.
Jarkko Kalliomäki is a specialist in pain and pain relief and holds an MD in Physiology. He has over ten years of experience as a Senior Clinical Research Physician at AstraZeneca R&D in Södertälje in several pain-related projects. He works as a consultant in rehabilitation medicine and pain relief at, among others, Sophiahemmet, PBM, and St. Göran's Hospital. Jarkko will support clinical management and work with the design and development of the clinical studies in close collaboration with Olof Breuer, CMO at PharmNovo.
OP Team steps up
PharmNovo AB is pleased to announce that the company has strengthened the team when entering the clinical phase with PN6047. Tommy Nilsson takes on the role of CFO, and Jarkko Kalliomäki will support clinical management and work with the design and development of clinical studies.
In August, PharmNovo started clinical studies of its drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain, after raising SEK 73 million in an issue led by Sciety earlier this summer.
Tommy Nilsson has a background as CFO at subsidiaries of Electrolux and Ericsson. He has worked as interim CFO for businesses in several industries for the past years. At PharmNovo, he will lead financial management and reporting, build up the company's routines and processes, and prepare the company for future follow-on financing.
Jarkko Kalliomäki is a specialist in pain and pain relief and holds an MD in Physiology. He has over ten years of experience as a Senior Clinical Research Physician at AstraZeneca R&D in Södertälje in several pain-related projects. He works as a consultant in rehabilitation medicine and pain relief at, among others, Sophiahemmet, PBM, and St. Göran's Hospital. Jarkko will support clinical management and work with the design and development of the clinical studies in close collaboration with Olof Breuer, CMO at PharmNovo.
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
